Joel Lewis Galectin Therapeutics Inc (GALT) insider trading activity

Joel Lewis is President and CEO of GALECTIN THERAPEUTICS INC. Currently has a direct ownership of 832,592 shares of GALT, which is worth approximately $4.73 Million. The most recent transaction as insider was on Mar 15, 2023, when has been sold 10,140 shares (Common Stock) at a price of $1.9 per share, resulting in proceeds of $19,266. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 833K

0% 3M change

7.25% 12M change

Total Value Held $4.73 Million

JOEL LEWIS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 15 2023	BUY Grant, award, or other acquisition	$19,266 $1.9 p/Share	10,140 Added 1.21%	830,439 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$156,345 $2.07 p/Share	75,529 Reduced 8.43%	820,299 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	$19,267 $2.07 p/Share	9,308 Added 1.03%	895,828 Common Stock
Feb 15 2023	BUY Grant, award, or other acquisition	$19,267 $1.44 p/Share	13,380 Added 1.49%	886,520 Common Stock
Feb 07 2023	BUY Grant, award, or other acquisition	$205,685 $1.43 p/Share	143,836 Added 14.14%	873,140 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	$17,499 $1.16 p/Share	15,086 Added 2.03%	729,304 Common Stock
Jan 13 2023	BUY Grant, award, or other acquisition	$17,500 $1.14 p/Share	15,351 Added 2.1%	714,218 Common Stock
Dec 30 2022	BUY Grant, award, or other acquisition	$17,500 $1.13 p/Share	15,487 Added 2.17%	698,867 Common Stock
Dec 15 2022	BUY Grant, award, or other acquisition	$17,499 $1.16 p/Share	15,086 Added 2.16%	683,380 Common Stock
Nov 30 2022	BUY Grant, award, or other acquisition	$17,500 $1.27 p/Share	13,780 Added 2.02%	668,294 Common Stock
Nov 15 2022	BUY Grant, award, or other acquisition	$17,500 $1.24 p/Share	14,113 Added 2.11%	654,514 Common Stock
Oct 31 2022	BUY Grant, award, or other acquisition	$17,499 $1.38 p/Share	12,681 Added 1.94%	640,401 Common Stock
Oct 14 2022	BUY Grant, award, or other acquisition	$17,499 $1.62 p/Share	10,802 Added 1.69%	627,720 Common Stock
Sep 30 2022	BUY Grant, award, or other acquisition	$19,217 $1.79 p/Share	10,736 Added 1.71%	616,918 Common Stock
Sep 15 2022	BUY Grant, award, or other acquisition	$17,501 $1.79 p/Share	9,777 Added 1.59%	606,182 Common Stock
Aug 31 2022	BUY Grant, award, or other acquisition	$17,501 $1.9 p/Share	9,211 Added 1.52%	596,405 Common Stock
Aug 15 2022	BUY Grant, award, or other acquisition	$17,501 $2.18 p/Share	8,028 Added 1.35%	587,194 Common Stock
Jul 29 2022	BUY Grant, award, or other acquisition	$23,970 $2.26 p/Share	10,606 Added 1.88%	552,139 Common Stock
Jul 15 2022	BUY Grant, award, or other acquisition	$17,500 $1.65 p/Share	10,606 Added 1.91%	544,396 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$17,500 $1.31 p/Share	13,359 Added 2.44%	533,790 Common Stock
Jun 15 2022	BUY Grant, award, or other acquisition	$17,776 $1.29 p/Share	13,780 Added 2.58%	520,431 Common Stock
May 31 2022	BUY Grant, award, or other acquisition	$17,500 $1.29 p/Share	13,566 Added 2.61%	506,651 Common Stock
May 13 2022	BUY Grant, award, or other acquisition	$17,500 $1.36 p/Share	12,868 Added 2.54%	493,085 Common Stock
Apr 29 2022	BUY Grant, award, or other acquisition	$17,499 $1.55 p/Share	11,290 Added 2.3%	480,217 Common Stock
Apr 15 2022	BUY Grant, award, or other acquisition	$17,499 $1.74 p/Share	10,057 Added 2.1%	468,927 Common Stock

Joel Lewis

President and CEO

Norcross, GA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GALT shares.

Notify only if

Value

Insider Trading

Get notified when an Galectin Therapeutics Inc insider buys or sells GALT shares.

Notify only if

Operation

Value

Type

News

Receive news related to GALECTIN THERAPEUTICS INC

Track Activities on GALT

Account